Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
1677results about "Special delivery" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Lipid formulation
Owner:ARBUTUS BIOPHARMA CORPORAT ION
Lipid formulations for nucleic acid delivery
The present invention provides novel, stable lipid particles comprising one or more active agents or therapeutic agents, methods of making the lipid particles, and methods of delivering and / or administering the lipid particles. More particularly, the present invention provides stable nucleic acid-lipid particles (SNALP) comprising a nucleic acid (such as one or more interfering RNA), methods of making the SNALP, and methods of delivering and / or administering the SNALP.
Owner:ARBUTUS BIOPHARMA CORPORAT ION
Lipid formulation
Owner:ARBUTUS BIOPHARMA CORPORAT ION
Lipid encapsulated interfering RNA
InactiveUS20060008910A1Inhibit aggregationReduce overexpressionBiocideOrganic active ingredientsLipid formationLipid particle
The present invention provides lipid-based formulations for delivering, e.g., introducing, nucleic acid-lipid particles comprising an interference RNA molecule to a cell, and assays for optimizing the delivery efficiency of such lipid-based formulations.
Owner:ARBUTUS BIOPHARMA CORPORAT ION
Nucleic Acid-Lipopolymer Compositions
InactiveUS20090042829A1Increase efficiency and dosing flexibilityEfficiently be lyophilizedSpecial deliveryPeptide/protein ingredientsCholesterolFiller Excipient
Compositions, methods, and applications that increase the efficiency of nucleic acid transfection are provided. In one aspect, a pharmaceutical composition may include at least about 0.5 mg / ml concentration of a nucleic acid condensed with a cationic lipopolymer suspended in an isotonic solution, where the cationic lipopolymer includes a cationic polymer backbone having cholesterol and polyethylene glycol covalently attached thereto, and wherein the molar ratio of cholesterol to cationic polymer backbone is within a range of from about 0.1 to about 10, and the molar ratio of polyethylene glycol to cationic polymer backbone is within a range of from about 0.1 to about 10. The composition further may include a filler excipient.
Owner:CLSN LAB
RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (SiNA)
InactiveUS20050032733A1Improve various propertyModulate its functionCompounds screening/testingSpecial deliveryBiological bodyNucleic acid sequencing
The present invention concerns methods and reagents useful in modulating gene expression in a variety of applications, including use in therapeutic, diagnostic, target validation, and genomic discovery applications. Specifically, the invention relates to synthetic chemically modified small nucleic acid molecules, such as short interfering nucleic acid (siNA), short interfering RNA (siRNA), double-stranded RNA (dsRNA), micro-RNA (miRNA), and short hairpin RNA (shRNA) molecules capable of mediating RNA interference (RNAi) against target nucleic acid sequences. The small nucleic acid molecules are useful in the treatment of any disease or condition that responds to modulation of gene expression or activity in a cell, tissue, or organism.
Owner:SIRNA THERAPEUTICS INC
RNA interference mediated inhibition of B-cell CLL/Lymphoma-2 (BCL-2) gene expression using short interfering nucleic acid (siNA)
InactiveUS20050176025A1Improves various propertyImprove the immunityCompounds screening/testingSpecial deliveryAutoimmune conditionAutoimmune disease
This invention relates to compounds, compositions, and methods useful for modulating BCL2 gene expression using short interfering nucleic acid (siNA) molecules. This invention also relates to compounds, compositions, and methods useful for modulating the expression and activity of other genes involved in pathways of BCL2 gene expression and / or activity by RNA interference (RNAi) using small nucleic acid molecules. In particular, the instant invention features small nucleic acid molecules, such as short interfering nucleic acid (siNA), short interfering RNA (siRNA), double-stranded RNA (dsRNA), micro-RNA (miRNA), and short hairpin RNA (shRNA) molecules and methods used to modulate the expression of BCL2 genes (e.g., BCL2, BCL-XL, BCL2-L1, MCL-1 CED-9, BAG-1, E1B-194 and / or BCL-A1). The small nucleic acid molecules are useful in the treatment of cancer, malignant blood disease, polycytemia vera, idiopathic myelofibrosis, essential thrombocythemia, myelodysplastic syndromes, autoimmune disease, viral infection, and proliferative diseases and conditions
Owner:SIRNA THERAPEUTICS INC
Cationic lipids and methods for the delivery of therapeutic agents
Owner:PROTIVA BIOTHERAPEUTICS
Lipid formulations for nucleic acid delivery
ActiveUS8283333B2Improve effectivenessHigh activityOrganic active ingredientsSugar derivativesLipid particleActive agent
The present invention provides novel, serum-stable lipid particles comprising one or more active agents or therapeutic agents, methods of making the lipid particles, and methods of delivering and / or administering the lipid particles. More particularly, the present invention provides serum-stable nucleic acid-lipid particles (SNALP) comprising a nucleic acid (e.g., one or more interfering RNA molecules), methods of making the SNALP, and methods of delivering and / or administering the SNALP (e.g., for the treatment of cancer). In particular embodiments, the present invention provides tumor-directed lipid particles that preferentially target solid tumors. The tumor-directed formulations of the present invention are capable of preferentially delivering a payload such as a nucleic acid to cells of solid tumors compared to non-cancerous cells.
Owner:ARBUTUS BIOPHARMA CORPORAT ION
Lipid encapsulated interfering RNA
The present invention provides lipid-based formulations for delivering, e.g., introducing, nucleic acid-lipid particles comprising an interference RNA molecule to a cell, and assays for optimizing the delivery efficiency of such lipid-based formulations.
Owner:ARBUTUS BIOPHARMA CORPORAT ION
RNA interference mediated inhibition of wingless gene expression using short interfering nucleic acid (siNA)
InactiveUS20050130181A1Improves various propertyImprove the immunityCompounds screening/testingSpecial deliveryWnt genesFhit gene
This invention relates to compounds, compositions, and methods useful for modulating wingless (WNT) gene expression using short interfering nucleic acid (siNA) molecules. This invention also relates to compounds, compositions, and methods useful for modulating the expression and activity of other genes involved in pathways of WNT gene expression and / or activity by RNA interference (RNAi) using small nucleic acid molecules. In particular, the instant invention features small nucleic acid molecules, such as short interfering nucleic acid (siNA), short interfering RNA (siRNA), double-stranded RNA (dsRNA), micro-RNA (miRNA), and short hairpin RNA (shRNA) molecules and methods used to modulate the expression of WNT genes such as WNT3A and WNT7A.
Owner:SIRNA THERAPEUTICS INC
Cationic lipids and methods for the delivery of therapeutic agents
InactiveUS20120202871A1Cyclic stabilitySize requirementBiocideOrganic active ingredientsLipid formationLipid particle
The present invention provides compositions and methods for the delivery of therapeutic agents to cells. In particular, these include novel cationic lipids and nucleic acid-lipid particles that provide efficient encapsulation of nucleic acids and efficient delivery of the encapsulated nucleic acid to cells in vivo. The compositions of the present invention are highly potent, thereby allowing effective knock-down of a specific target protein at relatively low doses. In addition, the compositions and methods of the present invention are less toxic and provide a greater therapeutic index compared to compositions and methods previously known in the art.
Owner:PROTIVA BIOTHERAPEUTICS
Compositions for targeted delivery of siRNA
The present invention is directed compositions for targeted delivery of RNA interference (RNAi) polynucleotides to hepatocytes in vivo. Targeted RNAi polynucleotides are administered together with co-targeted delivery polymers. Delivery polymers provide membrane penetration function for movement of the RNAi polynucleotides from outside the cell to inside the cell. Reversible modification provides physiological responsiveness to the delivery polymers.
Owner:ARROWHEAD MADISON
Compositions and methods for silencing apolipoprotein B
InactiveUS8236943B2Improve effectivenessHigh activityOrganic active ingredientsNanotechLipid particleApolipoproteins b
Owner:ARBUTUS BIOPHARMA CORPORAT ION
Compositions for Targeted Delivery of siRNA
The present invention is directed compositions for targeted delivery of RNA interference (RNAi) polynucleotides to hepatocytes in vivo. Targeted RNAi polynucleotides are administered together with co-targeted delivery polymers. Delivery polymers provide membrane penetration function for movement of the RNAi polynucleotides from outside the cell to inside the cell. Reversible modification provides physiological responsiveness to the delivery polymers.
Owner:ARROWHEAD MADISON
Novel cationic lipids and methods of use thereof
InactiveUS20130123338A1Cyclic stabilitySize requirementOrganic active ingredientsBiocideProtein targetLipid particle
The present invention provides compositions and methods for the delivery of therapeutic agents to cells. In particular, these include novel cationic lipids and nucleic acid-lipid particles that provide efficient encapsulation of nucleic acids and efficient delivery of the encapsulated nucleic acid to cells in vivo. The compositions of the present invention are highly potent, thereby allowing effective knock-down of a specific target protein at relatively low doses. In addition, the compositions and methods of the present invention are less toxic and provide a greater therapeutic index compared to compositions and methods previously known in the art.
Owner:PROTIVA BIOTHERAPEUTICS
Nucleic acid-containing lipid particles and related methods
ActiveUS20120276209A1Avoid mixingPowder deliveryOrganic active ingredientsLipid formationLipid particle
Lipid particles containing a nucleic acid, devices and methods for making the lipid particles, and methods for using the lipid particles.
Owner:THE UNIV OF BRITISH COLUMBIA
Novel lipid formulations for nucleic acid delivery
The present invention provides novel, stable lipid particles comprising one or more active agents or therapeutic agents, methods of making the lipid particles, and methods of delivering and / or administering the lipid particles. More particularly, the present invention provides stable nucleic acid-lipid particles (SNALP) comprising a nucleic acid (such as one or more interfering RNA), methods of making the SNALP, and methods of delivering and / or administering the SNALP.
Owner:ARBUTUS BIOPHARMA CORPORAT ION
Scaffolds for cell transplantation
ActiveUS20080044900A1Enhance cell viabilityIncrease successBioreactor/fermenter combinationsBiological substance pretreatmentsBiomedical engineeringCell biology
A device that includes a scaffold composition and a bioactive composition with the bioactive composition being incorporated into or coated onto the scaffold composition such that the scaffold composition and / or a bioactive composition controls egress of a resident cell or progeny thereof. The devices mediate active recruitment, modification, and release of host cells from the material.
Owner:RGT UNIV OF MICHIGAN +1
Compositions for enhancing transport of molecules into cells
ActiveUS7468418B2Easy to transportImprove bindingSpecial deliveryPeptide/protein ingredientsOligomerNucleic acid analog
Compositions and methods for enhancing delivery of molecules, e.g. biological agents, into cells are described. The composition is a conjugate of the biological agent, preferably a nucleic acid analog having a substantially uncharged backbone, covalently linked to a peptide transporter moiety as described. Conjugation of the peptide transporter to a substantially uncharged nucleic acid analog, such as a morpholino oligomer, is also shown to enhance binding of the oligomer to its target sequence and enhance antisense activity.
Owner:SAREPTA THERAPEUTICS INC
Peptide-based in vivo siRNA delivery system
The present invention is directed compositions for targeted delivery of RNA interference (RNAi) polynucleotides to hepatocytes in vivo. Targeted RNAi polynucleotides are administered together with co-targeted melittin delivery peptides. Delivery peptides provide membrane penetration function for movement of the RNAi polynucleotides from outside the cell to inside the cell. Reversible modification provides physiological responsiveness to the delivery peptides.
Owner:ARROWHEAD MADISON
Compositions for the delivery of therapeutic agents and uses thereof
InactiveUS20060051405A1Improve stabilityPromote accumulationSpecial deliveryMicroencapsulation basedLipid formationMedicine
The present invention provides drug delivery vehicles comprising polytheylyene-lipid conjugates (PEG-lipid), wherein the circulation lifetime and biodistribution of the drug delivery vehicles are regulated by the PEG-lipid. More particularly, the present invention provides liposomes, SNALP and SPLP comprising such PEG-lipid conjugates, and methods of using such compositions to selectively target a tumor site or other tissue of interest (e.g., liver, lung, spleen, etc.).
Owner:PROTIVA BIOTHERAPEUTICS
Trialkyl cationic lipids and methods of use thereof
The present invention provides compositions and methods for the delivery of therapeutic agents to cells. In particular, these include novel, trialkyl, cationic lipids and nucleic acid-lipid particles that provide efficient encapsulation of nucleic acids and efficient delivery of the encapsulated nucleic acid to cells in vivo. The compositions of the present invention are highly potent, thereby allowing effective knock-down of a specific target protein at relatively low doses.
Owner:ARBUTUS BIOPHARMA CORPORAT ION
Polyion complex of double-stranded ribonucleic acid
InactiveUS20120076836A1Easy and efficient deliverySmall particle sizePowder deliverySpecial deliveryDynamic light scatteringDouble strand
Provided are a delivery system that is useful in delivering a double-stranded ribonucleic acid that functions in gene silencing in glomeruli, particularly in mesangial cells and the like, to the tissue or cells, and the like. A polyion complex in the form of a non-polymeric micelle consisting of a double-stranded ribonucleic acid and a block copolymer represented by the formula (I) or (II) below, which are electrostatically bound together, wherein the polyion complex has an average particle diameter of less than 100 nm as measured by a dynamic light scattering measuring method:wherein each symbol is as defined in the specification.
Owner:THE UNIV OF TOKYO
Composition, method of preparation & application of concentrated formulations of condensed nucleic acids with a cationic lipopolymer
UndeterminedUS20090042825A1Increase efficiency and dosing flexibilitySpecial deliveryPeptide/protein ingredientsFiller ExcipientCholesterol
Compositions, methods, and applications that increase the efficiency of nucleic acid transfection are provided. In one aspect, a pharmaceutical composition may include at least about 0.5 mg / ml concentration of a nucleic acid condensed with a cationic lipopolymer suspended in an isotonic solution, where the cationic lipopolymer includes a cationic polymer backbone having cholesterol and polyethylene glycol covalently attached thereto, and wherein the molar ratio of cholesterol to cationic polymer backbone is within a range of from about 0.1 to about 10, and the molar ratio of polyethylene glycol to cationic polymer backbone is within a range of from about 0.1 to about 10. The composition further may include a filler excipient.
Owner:EXPRESSION GENETICS INC
Novel lipid formulations for delivery of therapeutic agents to solid tumors
ActiveUS20110076335A1Improve effectivenessFavorable toxicity profileOrganic active ingredientsSpecial deliveryLipid formationLipid particle
The present invention provides novel, serum-stable lipid particles comprising one or more active agents or therapeutic agents, methods of making the lipid particles, and methods of delivering and / or administering the lipid particles. More particularly, the present invention provides serum-stable nucleic acid-lipid particles (SNALP) comprising a nucleic acid (e.g., one or more interfering RNA molecules), methods of making the SNALP, and methods of delivering and / or administering the SNALP (e.g., for the treatment of cancer). In particular embodiments, the present invention provides tumor-directed lipid particles that preferentially target solid tumors. The tumor-directed formulations of the present invention are capable of preferentially delivering a payload such as a nucleic acid to cells of solid tumors compared to non-cancerous cells.
Owner:ARBUTUS BIOPHARMA CORPORAT ION
Glycoconjugates of RNA Interference Agents
ActiveUS20090203135A1Inhibit expression of target geneInhibit expressionOrganic active ingredientsSugar derivativesGlycoconjugateCancer research
The present invention relates to agents, compositions and methods for inhibiting the expression of a target gene, comprising an RNAi agent bearing at least one galactosyl moiety. These are useful for delivering the gene expression inhibiting activity to cells, particularly hepatocytes, and more particularly in therapeutic applications.
Owner:ALNYLAM PHARM INC
Polyconjugates for In Vivo Delivery of Polynucleotides
The present invention is directed to compounds, compositions, and methods useful for delivering polynucleotides or other cell-impermeable molecules to mammalian cells. Described are polyconjugates systems that incorporate targeting, anti-opsonization, anti-aggregation, and transfection activities into small biocompatible in vivo delivery vehicles. The use of multiple reversible or labile linkages connecting component parts provides for physiologically responsive activity modulation.
Owner:ARROWHEAD MADISON
RNA interference in respiratory epitheial cells
InactiveUS7297786B2Speed up the processAvoid insufficient lengthPowder deliveryBacteriaRespiratory epitheliumSmall interfering RNA
The present invention is directed to small interfering RNA molecules targeted against a gene of interest in respiratory epithelial cells, and methods of using these RNA molecules.
Owner:UNIV OF IOWA RES FOUND
Formulations comprising antisense nucleotides to connexins
InactiveUS7098190B1Reducing neuronal cell deathDown-regulated expressionNervous disorderSpecial deliveryNeuron cell deathWound healing
A therapeutic and / or cosmetic formulation comprising at least one anti-sense polynucleotide to a connexin protein together with a pharmaceutically acceptable carrier or vehicle is useful in site specific down regulation of connexin protein expression, particularly in reduction of neuronal cells death, wound healing, reduction of inflammation, decrease of scar formation and skin rejuvenation and thickening.
Owner:COLLEGE LONDON UNIV
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com